Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Metformin use linked to improved surgery outcomes

Publish date:: April 15, 2020

Key clinical point: Preoperative metformin may be associated with reduced postoperative mortality and readmission in patients with diabetes who undergo surgery.

Major finding: The 90-day, postsurgery mortality hazard was reduced by 28% in the metformin prescription recipients, compared with controls (HR, 0.72).

Study details: A retrospective cohort study of 10,088 surgery patients with diabetes.

Disclosures: The study was funded by the University of Pittsburgh Medical Center and by grants from the National Heart, Lung, and Blood Institute and the National Institutes of Health. Dr. Reitz reported having no disclosures.

Citation:

Reitz K et al. JAMA Surg. 2020 Apr 8. doi: 1001/jamasurg.2020.0416.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Annual WCC visits significantly limit asthma worsening,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

Must Reads in Diabetes

Sac/val heart failure benefit extends to diabetes patients,

Don’t miss cardiovascular risk factors in transgender patients,

Semaglutide shows promise in NASH phase 2 study,

Substance in tears could be used for diabetes monitoring,

EMPEROR-Reduced: Empagliflozin’s HFrEF benefit holds steady on top of sacubitril/valsartan,